Fiscal 2022 First Quarter Highlights
Net sales of $77.0 million increased 9.6% compared to the prior-year quarter
Gross margin of 52.1% increased 120 basis points year over year
GAAP loss per share of $0.18, and adjusted loss per share of $0.02
The Company commenced a Limited Market Release of its AlphaVac Mechanical Thrombectomy device in September
Updating Fiscal Year 2022 Financial Guidance
The Company now expects its fiscal year 2022 net sales to be in the range of $310 to $315 million, an increase from its prior guidance of $305 to $310 million. The Company expects gross margin to be approximately 55.0% and adjusted earnings per share in the range of $0.00 to $0.05 as it continues to invest in new product launches to drive future growth.
Conference Call
The Company's management will host a conference call today at 8:00 a.m. ET to discuss its first quarter results.
To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international) and refer to the passcode 13723182.
This conference call will also be webcast and can be accessed from the "Investors" section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
A recording of the call will also be available from 11:00 a.m. ET on Thursday, September 30, 2021, until 11:59 p.m. ET on Thursday, October 7, 2021. To hear this recording, dial 1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13723182.
https://finance.yahoo.com/news/angiodynamics-reports-fiscal-2022-first-110000246.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.